View in EDS HTML Full Text PDF Full Text

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.

Saved in:
Bibliographic Details
Title: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Authors: Pivonello R; Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy., Bancos I; Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, United States., Feelders RA; Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands., Kargi AY; Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Miami, Miami, FL, United States., Kerr JM; Department of Endocrinology, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, United States., Gordon MB; Allegheny Neuroendocrinology Center, Allegheny General Hospital, Pittsburgh, PA, United States., Mariash CN; Methodist Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States., Terzolo M; Department of Clinical and Biological Sciences, Internal Medicine 1 - San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy., Ellison N; Biostatistics, Trialwise, Inc, Houston, TX, United States., Moraitis AG; Drug Research and Development, Corcept Therapeutics, Menlo Park, CA, United States.
Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Jul 14; Vol. 12, pp. 662865. Date of Electronic Publication: 2021 Jul 14 (Print Publication: 2021).
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34335465
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pivonello+R%22">Pivonello R</searchLink>; Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Bancos+I%22">Bancos I</searchLink>; Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Feelders+RA%22">Feelders RA</searchLink>; Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Kargi+AY%22">Kargi AY</searchLink>; Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Miami, Miami, FL, United States.<br /><searchLink fieldCode="AU" term="%22Kerr+JM%22">Kerr JM</searchLink>; Department of Endocrinology, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, United States.<br /><searchLink fieldCode="AU" term="%22Gordon+MB%22">Gordon MB</searchLink>; Allegheny Neuroendocrinology Center, Allegheny General Hospital, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Mariash+CN%22">Mariash CN</searchLink>; Methodist Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Terzolo+M%22">Terzolo M</searchLink>; Department of Clinical and Biological Sciences, Internal Medicine 1 - San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.<br /><searchLink fieldCode="AU" term="%22Ellison+N%22">Ellison N</searchLink>; Biostatistics, Trialwise, Inc, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Moraitis+AG%22">Moraitis AG</searchLink>; Drug Research and Development, Corcept Therapeutics, Menlo Park, CA, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101555782%22">Frontiers in endocrinology</searchLink> [Front Endocrinol (Lausanne)] 2021 Jul 14; Vol. 12, pp. 662865. <i>Date of Electronic Publication: </i>2021 Jul 14 (<i>Print Publication: </i>2021).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101555782 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1664-2392 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216642392%22">16642392 </searchLink><i>NLM ISO Abbreviation: </i>Front Endocrinol (Lausanne) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34335465
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fendo.2021.662865
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 662865
    Titles:
      – TitleFull: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pivonello R
      – PersonEntity:
          Name:
            NameFull: Bancos I
      – PersonEntity:
          Name:
            NameFull: Feelders RA
      – PersonEntity:
          Name:
            NameFull: Kargi AY
      – PersonEntity:
          Name:
            NameFull: Kerr JM
      – PersonEntity:
          Name:
            NameFull: Gordon MB
      – PersonEntity:
          Name:
            NameFull: Mariash CN
      – PersonEntity:
          Name:
            NameFull: Terzolo M
      – PersonEntity:
          Name:
            NameFull: Ellison N
      – PersonEntity:
          Name:
            NameFull: Moraitis AG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 07
              Text: 2021 Jul 14
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 1664-2392
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Frontiers in endocrinology
              Type: main
ResultId 1